Med Page Today

MARCH 21, 2024

(MedPage Today) -- Medicare will cover the weight-loss drug semaglutide (Wegovy) under its Part D drug program for patients with overweight or obesity who have preexisting heart disease and need the drug to prevent heart attacks or strokes, the.

Medicare 132

Medicare Heart Attack Heart attacks Obesity 132

DAIC

JUNE 4, 2024

Stroke recovery is a challenging process that extends for months after hospital discharge. Navigating Post-Stroke Recovery at Home: One Patient's Experience A ”mildly impaired” stroke patient with atrial fibrillation who was discharged reported, “I knew my local pharmacist, and they knew my prescriptions.

Strokes 115

Strokes Stroke Innovation Research 115

DAIC

OCTOBER 15, 2024

15, 2024 – Elucid has announced that four of the seven Medicare Administrative Contractors (MACs) will extend coverage for AI-enabled quantitative coronary plaque analysis, including its FDA-cleared PlaqueIQ image analysis software, beginning Nov. tim.hodson Tue, 10/15/2024 - 12:12 Oct. For more information, please visit elucid.com.

Medicare 52

Medicare Plaque Chest Pain Coronary Artery Disease 52

DAIC

APRIL 24, 2024

Eighty percent of heart attacks and strokes are preventable. partially because its key risk factor, high blood pressure, is a ‘silent killer,’ and most patients have no symptoms before their first heart attack or stroke. Yet, CVD remains the leading cause of death in the U.S.,

Blood Pressure 116

Blood Pressure Cholesterol Technology Heart Attack 116

DAIC

MAY 16, 2024

A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD).

Peripheral Arterial Disease 105

Peripheral Arterial Disease Exercise Ischemia Quality of Life 105

DAIC

MARCH 7, 2024

Patients treated with CardiAMP cell therapy saw an almost 5% lower rate of heart death equivalents at up to two years compared to control patients treated with heart failure medication alone (8.3% vs. 13.2%, respectively). The CardiAMP HF II trial is expected to similarly secure CMS reimbursement.

Heart Failure 105

Heart Failure Biomarkers Reimbursement CMS 105

DAIC

JANUARY 27, 2025

13, 2025 Medtronic recentlyannounced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension.

CMS 52

CMS Blood Pressure Medicare Hypertension 52